{
  "id": 8291728,
  "title": "FDA approves Lilly's oral SERD combo for second-line breast cancer therapy",
  "url": "https://urgent.news/2026/09/18/fda-approves-lillys-oral-serd-combo-for-second-line-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T19:32:11.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-approves-lillys-oral-serd-combo-for-second-line-breast-cancer-therapy/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA has approved a new combination regimen from Eli Lilly for certain breast cancer patients. This regimen includes Lilly's oral selective estrogen receptor degrader (SERD) drug Inluriyo. According to Endpoints News, the approval is for second-line breast cancer therapy.\n\nThe approval is for patients with metastatic breast cancer.\n\nThere is no additional information in the reports to provide further details on the regimen or its usage.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nature Biotechnology",
        "title": "FDA approves pioneering breast cancer drug that nips resistance in the bud",
        "url": "https://urgent.news/2026/09/16/fda-approves-pioneering-breast-cancer-drug-that-nips-resistance-in",
        "published": "2026-09-16T00:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}